Inhibitex Veronate update
This article was originally published in Pharmaceutical Approvals Monthly
Panel of experts will review the firm's Veronate polyclonal immune globulin development program in May, with an assessment due "near the end of June," the firm says. However, "regardless of what we ultimately determine was the cause" of earlier disappointing Phase III results, the firm does not foresee conducting additional clinical trials in very low birth weight infants "with our current donor-selected immune globulin form" of the biologic, Inhibitex states April 28. Earlier in April, Inhibitex reported that Veronate missed all endpoints in a Phase III trial for prevention of hospital-associated infections in premature, very low birth weight infants. Inhibitex "will halt the manufacture of the clinical trial material it has used in the clinical development of Veronate to-date"...
You may also be interested in...
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
Agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give Biden team cushion to confirm a permanent leader of whom a top contender is former senior FDA staffer Joshua Sharfstein, a proponent of drug reforms that may irk manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.